David Young - 31 Dec 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
President & CEO, Director, 10%+ Owner
Signature
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
31 Dec 2022
Transactions value $
$0
Form type
4
Filing time
04 Jan 2023, 16:39:58 UTC
Previous filing
03 Oct 2022
Next filing
10 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +25,350 +6.76% $0 400,343 31 Dec 2022 Common Stock 25,350 $0 Direct F1
transaction PCSA Restricted Stock Units Award $0 +24,030 +6% $0 424,373 01 Jan 2023 Common Stock 24,030 $0 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the lessee's common stock upon the earliest of termination of employment, the third anniversary of the award date, a change of control, or the reporting person's death. These restricted stock units vest on date of grant.
F2 Each restricted stock units represents a contingent right to receive one share of the issuer's common stock, following its vesting of one-third on 01/01/24? 01/01/25 and 01/01/26, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death.